Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways

Journal of Cellular Physiology

Volumn 224, Issue 1, 2010, Pages 112-119

  Wei, Gang ^a   Wang, Meifang ^a   Carr, Brian I ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 METHYL 1 NAPHTHOL; CASPASE 3; CASPASE 8; FARNOQUINONE; FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHYTOMENADIONE; PROTEIN BCL 2; PROTEIN BID; RAF PROTEIN; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VITAMIN K GROUP; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; BID PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; FADD PROTEIN, HUMAN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FASLG PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN C JUN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; NICK END LABELING; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AGOUTI PACA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZENESULFONATES; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; PANCREATIC NEOPLASMS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-JUN; PYRIDINES; RAF KINASES; VITAMIN K 1;

EID: 77952498269     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22099     Document Type: Article

References (48)

1. Boucher MJ, Morisset J, Vachon PH, Reed JC, Lainé J, Rivard N. 2000. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79:355-369.
2. Carr BI, Wei G, Wang M. 2009. Vitamin k1 enhances Sorafenib effects on HCC and induces apoptosis: A non-toxic prevention strategy. AACR 100th Annual Meeting 1319.
3. Burris H III, Rocha-Lima C. 2008. New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13:289-298.
4. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. 1996. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271:31929-31936.
5. Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. 2007. Synergistic interactions between vorinostat and sorafenib in chronicmyelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 13:4280-4290.
6. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD. 2007. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209-2219.
7. Dent P, Qiao L, Gilfor D, Birrer M, Grant S, Fisher PB. 2003a. The regulation of tumor suppressor genes by oncogenes. Methods Mol Biol 222:269-292.
8. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. 2003b. MAPK pathways in radiation responses. Oncogene 22:5885-5896.
9. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF, Jr. 1995. Recent cancer trends in the United States. J Natl Cancer Inst 87:175-182.
10. Elmore S. 2007. Apoptosis: A review of programmed cell death. Toxicol Pathol 35:495-516.
11. Flaherty KT. 2007. Sorafenib: Delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 7:617-626.
12. Gillenwater AM, Zhong M, Lotan R. 2007. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through bothmitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 6:2967-2975.
13. Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G, Janssen JW, Bartram CR. 1989. High frequency of Ki-ras codon 127 mutations in pancreatic adenocarcinomas. Int J Cancer 43:1037-1041.
14. Hibi M, Lin A, Smeal T, Minden A, Karin M. 1993. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135-2148. (Pubitemid 23336140)
15. Holmström TH, Schmitz I, Söderström TS, Poukkula M, Johnson VL, Chow SC, Krammer PH, Eriksson JE. 2000. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J 19:5418-5428.
16. Ishimura N, Yamasawa K, Karim Rumi MA, Kadowaki Y, Ishihara S, Amano Y, Nio Y, Higami T, Kinoshita Y. 2003. BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett 199:169-173.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
18. Jia L, Yu W, Wang P, Li J, Sanders BG, Kline K. 2008. Critical roles for JNK, c-Jun, and Fas/FasL-signaling in vitamin E analog-induced apoptosis in human prostate cancer cells. Prostate 68:427-441.
19. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R. 2006. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278.
20. Karin M, Gallagher E. 2005. From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance IUBMB Life. 57:283-295.
21. Kaufmann SH, Hengartner MO. 2001. Programmed cell death: Alive and well in the new millennium. Trends Cell Biol 11:526-534.
22. Kavurma MM, Khachigian LM. 2003. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 10:36-44.
23. Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ, Hur DY. 2008. Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. J Immunol 181:6158-6169.
24. Lasham A, Lindridge E, Rudert F, Onrust R, Watson J. 2000. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 252:1-13.
25. Lin A, Dibling B. 2002. The true face of JNK activation in apoptosis. Aging Cell 1:112-116.
26. Liu J, Lin A. 2005. Role of JNKactivation in apoptosis: Adouble-edged sword. Cell Res 15:36-42.
27. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. 2006. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858.
28. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
29. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. 2003. Sustained activation of JNK/p38MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278:19245-19256.
30. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. 2001. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108:851-859.
31. Motojima K, Urano T, Nagata Y, Shiku H, Tsurifune T, Kanematsu T. 1993. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg 217:138-143. (Pubitemid 23059284)
32. Osada S, Tomita H, Tanaka Y, Tokuyama Y, Tanaka H, Sakashita F, Takahashi T. 2008. The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res 28:45-50. (Pubitemid 351362879)
33. Otsuka M, Kato N, Shao RX, Hoshida Y, Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T, Omata M. 2004. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 40:243-251.
34. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, et al. 2006. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512. (Pubitemid 46630627)
35. Rini BI. 2006. Sorafenib. Expert Opin Pharmacother 7:453-461.
36. Sata N, Klonowski-Stumpe H, Han B, Häussinger D, Niederau C. 1997. Menadione induces both necrosis and apoptosis in rat pancreatic acinar AR4-2J cells. Free Radic Biol Med 23:844-850.
37. Shibayama-Imazu T, Sakairi S, Watanabe A, Aiuchi T, Nakajo S, Nakaya K. 2003. Vitamin K(2) selectively induced apoptosis in ovarian TYK-nu and pancreatic MIA PaCa-2 cells out of eight solid tumor cell lines through a mechanism different from geranylgeraniol. J Cancer Res Clin Oncol 129:1-11. (Pubitemid 36403253)
38. Shiraki M, Shiraki Y, Aoki C, Miura M. 2000. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15:515-521. (Pubitemid 30134096)
39. Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, Moore MJ. 2006. Phase I trial of sorafenib and gemcitabine in advanced solid tumorswith an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12:144-151.
40. Strumberg D. 2005. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 41:773-784.
41. Tanimura S, Uchiyama A, Watanabe K, Yasunaga M, Inada Y, Kawabata T, Iashita K, Noda S, Ozaki K, Kohno M. 2009. Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells. Biochem Biophys Res Commun 378:650-655.
42. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette DC, Birchenall-Roberts MC. 1997. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res 57:881-890. (Pubitemid 27098013)
43. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W. 2009. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 220:214-221.
44. Wilhelm S, Chien DS. 2002. BAY 43-9006: Preclinical data. Curr Pharm Des 8:2255-2257.
45. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109.
46. Wilson DJ, Alessandrini A, Budd RC. 1999. MEK1 activation rescues Jurkat T cells from Fas-induced apoptosis. Cell Immunol 194:67-77.
47. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. 2008a. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 10:184-198.
48. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M. 2008b. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22:808-818.